Clinical trials: Diabetes, Type II
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as…
- Trial name
- NCT01515657
- Testing
- PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- PLx Pharma
Type 2 Diabetes Mellitus
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in…
- Trial name
- NCT00789750
- Testing
- Colesevelam, Pioglitazone
- Where
- 141 sites in United States
- Volunteers
- 562 people
- Sponsor
- Daiichi Sankyo
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
- Trial name
- TRENDS (NCT03014479)
- Testing
- Trelagliptin, Daily DPP-4 inhibitor
- Where
- 27 sites in Japan
- Volunteers
- 219 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- JANUB48 (NCT01334229)
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Type2 Diabetes
OP5-005 Using Omnipod 5 in Adults With Type 2
This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.
- Trial name
- SECURE-T2D (NCT05815342)
- Testing
- Omnipod 5 Automated Glucose Control System
- Where
- 21 sites in United States
- Volunteers
- 343 people
- Sponsor
- Insulet Corporation
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Primary Objective: To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: To assess the effect of the 2 lixisenatide regimens on: The…
- Trial name
- NCT01517412
- Testing
- Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin
- Where
- 82 sites in United States, Canada and 8 more
- Volunteers
- 451 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Effect of DPP4 Inhibition on Vasoconstriction
The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in diabetics affects hemodynamic parameters and sympathetic activation in the setting of increasing concentrations of neuropeptide Y, an…
- Trial name
- NCT02639637
- Testing
- Sitagliptin, Neuropeptide Y, Enalaprilat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University
Type 2 Diabetes Mellitus
Initial Combination With Pioglitazone Study (0431-064)
A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.
- Trial name
- NCT00397631
- Testing
- sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypogonadism
Testosterone Replacement in Men With Diabetes and Obesity
The purpose of this study is to examine the effect of having testosterone deficiency in men with diabetes and with obesity. The study will also evaluate the effect of testosterone therapy.
- Trial name
- NCT01127659
- Testing
- testosterone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Type 2
A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients
This study is designed to look at if a basal bolus regimen of insulin lispro protamine suspension (ILPS) provides the same glycemic control as a basal bolus regimen of insulin glargine (when one basal bolus regimen is injected…
- Trial name
- NCT00666718
- Testing
- Insulin Glargine, Insulin Lispro Protamine Suspension (ILPS), Insulin Lispro
- Where
- 50 sites in Belgium, Czechia and 8 more
- Volunteers
- 374 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose…
- Trial name
- DUALTM IX (NCT02773368)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 88 sites in United States, Argentina and 9 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Diabetes Mellitus, Type 2
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
- Trial name
- NCT01774968
- Testing
- Human Regular U-500 Insulin
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes
- Trial name
- NCT03005288
- Testing
- BYM338 10 mg/kg
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
Specific Aim 1.To examine whether the combination of liraglutide plus canagliflozin can prevent the increase in Hepatic Glucose Production (HGP) following institution of canagliflozin therapy and produce an additive or even…
- Trial name
- NCT02324842
- Testing
- Canagliflozin, Liraglutide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes, Chronic Kidney Diseases
Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD
In Aim 1 of this study, the investigators will utilize community organizations to screen Hispanics/Latino(a)s for kidney disease, diabetes, and other risk factors, and refer them for care with a PCP.
- Trial name
- NCT05734989
- Testing
- BP, HbA1c, PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Duke University
Type 2 Diabetes, Hypertension
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Insulin resistance has been implicated as the central pathogenetic feature of cardiovascular risk factor cluster that includes hypertension, impaired glucose tolerance, diabetes, dyslipidemia, and hemostatic disorders.
- Trial name
- NCT00738023
- Testing
- Rosiglitazone, Normal saline 0.9%, Intralipid 20%
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Emory University
Diabetes Mellitus, Hypertension
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and…
- Conditions
- Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity
- Trial name
- NCT00001723
- Testing
- Orlistat
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jack Yanovski
Non Insulin Dependent Diabetes, Pregnancy
Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
Many women come into pregnancy with diabetes that is controlled with either Metformin or diet control; however, the current standard of care for the treatment of preexisting diabetes in pregnancy is insulin.
- Trial name
- MIPOD (NCT00835861)
- Testing
- Metformin, Insulin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of North Carolina, Chapel Hill
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.